Home > Riviste > Minerva Ginecologica > Fascicoli precedenti > Minerva Ginecologica 2016 Dicembre;68(6) > Minerva Ginecologica 2016 Dicembre;68(6):668-74

ULTIMO FASCICOLOMINERVA GINECOLOGICA

Rivista di Ostetricia e Ginecologia


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

REVIEWS  


Minerva Ginecologica 2016 Dicembre;68(6):668-74

lingua: Inglese

Fertility preservation options for prepubertal boys facing gonadotoxic therapies

Ahmed A. HUSSEIN 1, Pamela YANGO 2, Youseff EZZ 1, James F. SMITH 2, 3, Nam D. TRAN 2

1 Department of Urology, Cairo University, Il Cairo, Egypt; 2 Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA, USA; 3 Department of Urology, University of California, San Francisco, CA, USA


PDF  ESTRATTI


Infertility is a common disease affecting 10-15% of reproductive couples with significant psychological and financial impacts to both patients and society. Approximately 80 million people worldwide are infertile, with an increasing incidence of male infertility. Semen cryopreservation in adults is a proven method of fertility preservation for male patients undergoing gonadal toxic therapies. Unlike adults who can cryopreserve sperm at any time prior to gonadal toxic treatments, there are no effective fertility preservation options for children undergoing cancer treatment, a time when semen cryopreservation is not feasible. Thus, most of the childhood cancer survivor will develop irreversible azoospermia due to the gonadal toxicity of the treatment on spermatogononial stem cells. This review will summarize the possible options and challenges of fertility preservation in this vulnerable population.

inizio pagina